Our results show that p-PKR and p-eIF2α are predictive biomarkers of NSCLC outcomes and that when expression of PKR was combined with expression of p-PKR or p-eIF2α, the effect on predicting patient survival was enhanced. The gene discussed is EIF2AK2; the disease is non-small cell lung carcinoma.